The impact of body weight on ovarian cancer outcomes

International Journal of Gynecological Cancer

Volumn 21, Issue 9, 2011, Pages 1601-1605

  Backes, Floor J ^a   Nagel, Christa I ^b   Bussewitz, Elizabeth ^a   Donner, Jessica ^a   Hade, Erinn ^a   Salani, Ritu ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Body mass index; Obesity; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BODY MASS; BODY WEIGHT; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OBESITY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; WEIGHT CHANGE; WEIGHT GAIN; ADJUVANT CHEMOTHERAPY; MIDDLE AGED; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY WEIGHT; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OBESITY; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; THINNESS; TREATMENT OUTCOME;

EID: 84857436406     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31822d2aa3     Document Type: Article

References (24)

1. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-2850. (Pubitemid 38747805)
2. Rapp K, Klenk J, Ulmer H, et al. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann Oncol. 2008;19:641-648. (Pubitemid 351461032)
3. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79. (Pubitemid 36026281)
4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-591. (Pubitemid 39025053)
5. Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43:690-709. (Pubitemid 46502901)
6. Zang M, Xie X, Lee AH, et al. Body mass index in relation to ovarian cancer survival. Cancer Epidemiol Biomarkers Prev. 2005;14:1307-1310. (Pubitemid 40656486)
7. Münstedt K, Wagner M, Kullmer U, et al. Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control. 2008;19:909-916.
8. Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006;107: 1520-1524. (Pubitemid 44546912)
9. Barrett SV, Paul J, Hay A, et al. Scottish Gynaecological Cancer Trials Group. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol. 2008;19:898-902. (Pubitemid 351627304)
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
11. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;B34:187-220.
12. Engeland A, Tretli S, Bjorge T. Height, body mass index and ovarian cancer: a follow up of 1.1 million Norwegian women. J Natl Cancer Instit. 2003;16:1244-1248. (Pubitemid 37069556)
13. Purdie DM, Bain CJ, Webb PM, et al. Body size and ovarian cancer: case-control study and systematic review. Cancer Causes Control. 2001;12:855-863. (Pubitemid 33010624)
14. Prentice RL, Thomson CA, Caan B, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99:1534-1543. (Pubitemid 351767234)
15. Thomson CA, Alberts DS. Diet and survival after ovarian cancer: where are we and what's next? J Am Diet Assoc. 2010;110:366-368.
16. Matthews KS, Straughn Jr JM, Kemper MK, et al. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol. 2009;112:389-393.
17. Skirnisdottir I, Sorbe B. Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:345-351. (Pubitemid 351365212)
18. Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:353-358.
19. Ekhart C, Rodenhuis S, Schellens JH, et al. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol. 2009;64:115-122.
20. Fotopoulou C, Richter R, Braicu EI, et al. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking. Ann Surg Oncol. 2011;18:2629-2637.
21. Hess LM, Barakat R, Tian C, et al. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;107:260-265. (Pubitemid 47575723)
22. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008;26:4109-4115.
23. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24:3535-3541. (Pubitemid 46630523)
24. Gil KM, Frasure HE, Hopkins MP, et al. Body weight and composition changes in ovarian cancer patients during adjuvant chemotherapy. Gynecol Oncol. 2006;103:247-252. (Pubitemid 44389870)